Dr. Chris Shoemaker explains how DARPA recommended ivermectin for corona virus to the CDC following a 15 years study ending in 2015.
Dr. Chris Shoemaker is a licensed Comprehensive Physician in Ontario and member of the College of Family Physicians of Canada (CCFP) with 45 years of service in both Ontario and British Columbia. More recently in 2020 through 2022 he worked in direct patient care at the West Ottawa Covid Care Clinic, and was part of the Eastern Ontario Response Team to Covid-19. Based on studies out of Britain in Jan 2021 – May 2022, he describes a one in 3 Billion event and has declared the need to ‘Save the Children – End the Vaxx’.
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Els Keyaerts, Leen Vijgen, Piet Maes, Johan Neyts, and Marc Van Ranst*
Author information Article notes Copyright and License information Disclaimer
Abstract
We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC50 of chloroquine for antiviral activity (8.8 ± 1.2 μM) was significantly lower than its cytostatic activity; CC50 (261.3 ± 14.5 μM), yielding a selectivity index of 30. The IC50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.
Keywords: SARS-CoV, Severe acute respiratory syndrome, Coronavirus, Chloroquine, Antiviral activity
Severe acute respiratory syndrome (SARS) has recently emerged as a new highly contagious human disease with a major impact all over the world [1]. The global SARS epidemic started in the Guangdong Province in southern China, where several cases of atypical pneumonia of unknown etiology were reported at the end of November 2002. A novel member of the Coronaviridae family has been identified as the causative agent of SARS [2], [3], [4], [5], [6], [7]. Three other human coronaviruses (HCoV) OC43, 229E, and the recently characterized NL63 are important causes of upper respiratory tract illnesses. In late fall and winter they are responsible for approximately one-third of the common colds.
The rest of the article is here: https://ncbi.nlm.nih.gov/pmc/articles/PMC7092815/
Biochem Biophys Res Commun. 2004 Oct 8; 323(1): 264–268.
Published online 2004 Aug 28. doi: 10.1016/j.bbrc.2004.08.085
PMCID: PMC7092815
PMID: 15351731
budbromley 